CA Patent

CA2868026C — Compounds for treating spinal muscular atrophy

Assigned to PTC Therapeutics Inc · Expires 2021-02-16 · 5y expired

What this patent protects

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. The compounds have the following general formula: (see formula Ia1) or a free acid, free base, salt, isotopologue, stereoisomer, racemate, enantiomer, diastereomer or taut…

USPTO Abstract

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. The compounds have the following general formula: (see formula Ia1) or a free acid, free base, salt, isotopologue, stereoisomer, racemate, enantiomer, diastereomer or tautomer thereof.

Drugs covered by this patent

Patent Metadata

Patent number: CA2868026C
Jurisdiction: CA
Classification: —
Expires: 2021-02-16
Drug substance claim: No
Drug product claim: No
Assignee: PTC Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.